Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Innovent Biologics (Suzhou) Co., Ltd

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

Not yet recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Taletrectinib

First Posted Date: 2025-06-06

Last Posted Date: 2025-06-06

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 100

Registration Number: NCT07008287

Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity

Phase 1

Not yet recruiting

Conditions: Obesity

Interventions: Drug: IBI362
Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2025-06-03

Last Posted Date: 2025-06-03

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 98

Registration Number: NCT07000955

Locations: 🇨🇳
The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Unresectable Locally Advanced or Metastatic Solid Tumors

Interventions: Drug: IBI3014

First Posted Date: 2025-05-16

Last Posted Date: 2025-05-16

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 250

Registration Number: NCT06974812

Locations: 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China

A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants

Phase 1

Recruiting

Conditions: Asthma

Interventions: Drug: IBI3002
Drug: Placebo

First Posted Date: 2025-04-27

Last Posted Date: 2025-05-28

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 60

Registration Number: NCT06947408

Locations: 🇨🇳
China-japan Friendship Hosipital, Beijing, Beijing, China

A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Phase 2

Not yet recruiting

Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH)

Interventions: Drug: IBI362
Drug: Placebo

First Posted Date: 2025-04-22

Last Posted Date: 2025-04-22

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 165

Registration Number: NCT06937749

Locations: 🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China

A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2

Phase 3

Recruiting

Conditions: Sleep Apnea
Obstructive
Obesity

Interventions: Other: placebo
Drug: IBI362

First Posted Date: 2025-04-16

Last Posted Date: 2025-06-29

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 260

Registration Number: NCT06931028

Locations: 🇨🇳
Peking University Third Hospital, Beijing, China

A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）

Phase 3

Recruiting

Conditions: Overweight
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

Interventions: Drug: semaglutide
Drug: IBI362

First Posted Date: 2025-03-19

Last Posted Date: 2025-05-14

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 470

Registration Number: NCT06884293

Locations: 🇨🇳
Beijing Hospital, Beijing, Beijing, China

A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity

Phase 2

Recruiting

Conditions: Obesity
Heart Failure With Preserved Ejection Fraction (HFPEF)
Heart Failure With Mildly Reduced Ejection Fraction

Interventions: Drug: IBI362
Other: placebo

First Posted Date: 2025-03-06

Last Posted Date: 2025-04-27

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 141

Registration Number: NCT06862908

Locations: 🇨🇳
Fuwai Hospital, CAMS&PUMC, Beijing, Beijing, China

Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3

Recruiting

Conditions: Ovarian
Primary Peritoneal
Fallopian Tube Cancer

Interventions: Drug: IBI354
Drug: paclitaxel/Gemcitabine/Liposomal doxorubicin

First Posted Date: 2025-02-19

Last Posted Date: 2025-04-13

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 450

Registration Number: NCT06834672

Locations: 🇨🇳
Affiliated Cancer Hospital of Chongqing University, Chongqing, Chongqing, China

A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy

Phase 2

Recruiting

Conditions: Melanoma

Interventions: Biological: IBI363
Biological: Pembrolizumab

First Posted Date: 2025-01-28

Last Posted Date: 2025-04-04

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 180

Registration Number: NCT06797297

Locations: 🇨🇳
First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Beijing Jishuitan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Peking University Cancer Hospital & Institute, Beijing, China,, Beijing, Beijing, China

and more 28 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy